NEW YORK(GenomeWeb) – Roche today said it has extended the expiration of its tender offer for common shares of Foundation Medicine to midnight EST at the end of the day April 6.
The tender offer for 15,604,288 shares of Foundation's stock at $50 per share is part of a $1.2 billion stake that Roche plans to take in the Cambridge, Mass.-based cancer molecular diagnostics firm. All other terms and conditions of the tender offer remain the same.
As of March 1, about 7.7 million shares of Foundation had been tendered and not withdrawn, Roche said, adding that it does not anticipate a further extension of the tender offer.